Semaglutide: The Approved Benchmark

The short version

Semaglutide is a GLP-1 receptor agonist — a lab-made peptide that copies a gut hormone called GLP-1, which the body releases after eating to signal fullness and steady blood sugar. It is approved by the FDA for type 2 diabetes, long-term weight management, lowering cardiovascular risk in people who already have heart disease, and, since 2025, a liver condition called MASH. It comes as a once-weekly injection or a daily pill.

In its largest weight-loss trial, people taking semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo ^[4]. In a trial of more than 17,000 people with existing heart disease, it cut the risk of a major cardiac event by about a fifth ^[3]. In people with diabetes and kidney disease, it lowered the risk of serious kidney problems by roughly a quarter ^[2].

The honest context: semaglutide is no longer the strongest performer in its own class. A head-to-head trial found a newer dual-action peptide produced substantially more weight loss ^[1]. This page reports what was studied — it does not recommend a dose or a course of treatment for anyone.

What it is

Semaglutide is a 31-amino-acid peptide built on the structure of human GLP-1, sharing roughly 94% of its sequence with the natural hormone. Two substitutions give it staying power in the body: at position 8, a protease-resistant amino acid replaces the one that native GLP-1 loses within minutes; at position 34, a second swap adds further stability. The remaining lysine, at position 26, carries a fatty acid side chain that binds strongly and reversibly to albumin, the most abundant protein in blood plasma. That albumin binding shields the peptide from rapid clearance, extending its circulating half-life to roughly a week and making once-weekly dosing possible.

The oral tablet form is co-formulated with an absorption enhancer that briefly changes conditions at a small patch of stomach lining, allowing a fraction of the peptide through before digestive enzymes break it down. Oral bioavailability stays low even so, which is why the tablet requires strict fasted administration.

How it works

Semaglutide activates GLP-1 receptors throughout the body. In the pancreas it boosts insulin release only when blood sugar is already elevated, and dampens glucagon, the hormone that raises blood sugar — a glucose-dependent mechanism that limits the risk of dangerously low blood sugar when used alone. It also slows gastric emptying, which blunts post-meal glucose spikes and is a major reason for the nausea some people experience.

Its weight effect is largely centred in the brain. The peptide reaches appetite circuits in the hypothalamus and brainstem, activating neurons that signal fullness and suppressing the ones that drive hunger. This is the biological basis for what many people using it describe as a quieting of near-constant background thoughts about food, sometimes called 'food noise.' Beyond glucose and appetite, GLP-1 receptors on heart and kidney tissue appear to carry protective effects that large outcome trials have since confirmed ^[2][3].

What the research shows

Head-to-head against a newer agent. In the SURMOUNT-5 trial, 751 adults with obesity were randomized to the maximum tolerated dose of either semaglutide or a newer dual-receptor peptide. The comparison drug produced 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks, a statistically significant gap of about 6.5 percentage points ^[1].

Weight management. In the STEP 1 trial of 1,961 adults with overweight or obesity and no diabetes, once-weekly semaglutide 2.4 mg produced a mean 14.9% weight reduction at 68 weeks versus 2.4% with placebo ^[4].

Cardiovascular outcomes. In SELECT, a trial of 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, semaglutide reduced the combined risk of cardiovascular death, heart attack or stroke by 20% relative to placebo (hazard ratio 0.80) ^[3].

Kidney outcomes. In FLOW, a trial of 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide reduced the risk of major kidney-disease events by 24% versus placebo (hazard ratio 0.76) ^[2].

Safety profile. A dedicated safety review describes semaglutide's overall risk-benefit balance as favourable in type 2 diabetes, with gastrointestinal effects — nausea in roughly a third of patients — as the dominant complaint, alongside an increased risk of gallbladder disease and pancreatic- or thyroid-cancer signals that remain unconfirmed because of low event numbers ^[5].

Reported effects, cautions & safety

People using semaglutide describe a fairly consistent cluster of effects in patient communities and published patient-experience surveys — anecdotal, not clinical evidence, and never a basis for choosing a dose.

Reported benefits: the most frequent description is a sharp quieting of food preoccupation, alongside steady weight loss over months, improved blood-sugar readings among people with diabetes, and, less predictably, reduced interest in alcohol.

Reported adverse effects: nausea is the most common complaint, typically peaking during dose increases and easing as the body adjusts. Sulfur-smelling burps, changes in bowel habits, reflux, and early fatigue on injection days are also frequently mentioned, along with occasional hair shedding that people generally attribute to the pace of weight loss rather than the medication itself.

Cited cautions from the clinical literature:

• Gastrointestinal intolerance during dose escalation is the leading adverse effect in trials and the main reason people stop treatment ^[5].
• A boxed warning for thyroid C-cell tumours stems from rodent data; a personal or family history of medullary thyroid carcinoma or MEN-2 is treated as a contraindication, though no clear human signal has been established ^[5].
• Acute pancreatitis is a class warning for this drug family, though a confirmed increase in pancreatic cancer risk has not been established ^[5].
• Gallbladder disease risk is measurably increased, attributed largely to the pace and scale of weight loss ^[5].
• Diabetic retinopathy complications were more frequent in a trial of people with diabetes undergoing rapid blood-sugar correction while on semaglutide ^[5].
• Lean muscle mass loss occurs alongside fat loss, raising concern for older adults in particular ^[5].
• Weight tends to return after stopping: trial extensions show substantial regain within a year of discontinuation, framing this as a long-term rather than short-course treatment ^[5].

Where it fits in the global research map

Semaglutide is the FDA-approved anchor of this desk — the compound with the deepest, most internationally distributed trial programme of the four. Its SELECT and FLOW outcome trials each enrolled thousands of participants, the kind of scale that a single, well-funded regulatory pathway makes possible ^[2][3]. Set against thymosin alpha-1, which is approved abroad but not in the US, or BPC-157 and MOTS-c, which are approved nowhere, semaglutide illustrates the other end of the spectrum this site is mapping: what a peptide's evidence base looks like once formal drug approval opens the door to large, coordinated, regulator-overseen trials. See the comparison page for the full picture across all four.